Profile data is unavailable for this security.
About the company
Avacta Group plc is a United Kingdom-based life sciences company developing peptide drug conjugates (PDC) targeting anti-tumor payloads directly to the tumor. The Company is focused on the development of its proprietary preCISION technology platform. The preCISION platform is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The preCISION platform harnesses this tumor-specific protease to cleave preCISION peptide drug conjugates and preCISION antibody/Affimer drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity. Its lead program, AVA6000, is a clinical-stage asset which is a preCISION-enabled form of doxorubicin. AVA6103, the Company’s second program, is a preCISION-enabled PDC comprised of the preCISION peptide linked to exatecan, the most potent topoisomerase I (topo I) inhibitor in clinical development.
- Revenue in GBP (TTM)-11.09m
- Net income in GBP-33.09m
- Incorporated2003
- Employees151.00
- LocationAvacta Group PLCUnit 20, Ash WayWETHERBY LS23 7FAUnited KingdomGBR
- Phone+44 190 421 7070
- Fax+44 844 414 0453
- Websitehttps://avacta.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Skinbiotherapeutics PLC | 4.64m | -696.25k | 54.37m | 41.00 | -- | 5.77 | -- | 11.72 | -0.0032 | -0.0032 | 0.0204 | 0.0364 | 0.5349 | 2.80 | 4.81 | 113,125.60 | -8.03 | -44.16 | -9.90 | -53.32 | 61.65 | -- | -15.01 | -175.65 | 4.29 | -12.21 | 0.0954 | -- | 283.74 | -- | 75.79 | -- | 16.61 | -- |
| Hemogenyx Pharmaceuticals PLC | 0.00 | -7.81m | 59.93m | 16.00 | -- | -- | -- | -- | -2.21 | -2.21 | 0.00 | -0.1089 | 0.00 | -- | -- | 0.00 | -169.60 | -87.04 | -210.76 | -102.48 | -- | -- | -- | -- | -- | -2.14 | 1.33 | -- | -- | -- | 16.01 | -- | 2.20 | -- |
| 4Basebio PLC | 1.78m | -14.41m | 87.02m | -- | -- | 4.57 | -- | 48.91 | -0.9923 | -0.9923 | 0.1226 | 1.23 | 0.0729 | 1.54 | 21.56 | -- | -59.05 | -36.81 | -64.81 | -40.98 | 61.55 | 69.88 | -809.95 | -1,160.83 | 11.15 | -95.30 | 0.4485 | -- | 84.39 | 35.80 | -60.90 | -- | 50.57 | -- |
| Bioventix PLC | 13.12m | 7.58m | 90.91m | 16.00 | 12.06 | 7.87 | 11.84 | 6.93 | 1.44 | 1.44 | 2.49 | 2.21 | 0.9864 | 1.84 | 2.10 | 819,741.90 | 57.04 | 58.17 | 64.40 | 64.19 | 90.86 | 92.79 | 57.83 | 61.84 | 8.65 | -- | 0.00 | 105.34 | -3.61 | 4.92 | -6.33 | 1.04 | -43.71 | 11.26 |
| Scancell Holdings Plc | 4.71m | -5.51m | 134.91m | 60.00 | -- | -- | -- | 28.64 | -0.0053 | -0.0053 | 0.0047 | -0.0081 | 0.2946 | -- | 8.26 | 78,516.66 | -34.46 | -33.29 | -- | -44.23 | 94.95 | -- | -116.98 | -502.03 | -- | -- | 2.07 | -- | -- | -- | -109.46 | -- | 124.48 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.94m | 188.15m | 25.00 | -- | -- | -- | -- | -0.2522 | -0.2522 | 0.00 | -0.1352 | 0.00 | -- | -- | 0.00 | -119.80 | -227.46 | -304.25 | -1,738.54 | -- | -- | -- | -- | -- | -1.65 | 3.64 | -- | -- | -- | 16.24 | -- | 17.71 | -- |
| Avacta Group Plc | -11.09m | -33.09m | 264.25m | 151.00 | -- | 1,640.38 | -- | -- | -0.0891 | -0.1579 | -0.0298 | 0.0004 | -0.1872 | -- | -- | -73,456.95 | -55.83 | -43.48 | -129.38 | -78.27 | -- | 63.54 | -- | -781.44 | 0.7883 | -0.4837 | 0.993 | -- | -96.04 | -- | -0.9503 | -- | -- | -- |
| Puretech Health PLC | 4.73m | 37.47m | 309.84m | 56.00 | 8.37 | 1.11 | 11.86 | 65.57 | 0.1532 | 0.1532 | 0.0196 | 1.16 | 0.0113 | -- | 2.81 | 84,380.60 | 5.63 | -3.27 | 6.57 | -3.83 | -- | -- | 498.87 | -253.25 | -- | -- | 0.0537 | -- | 44.98 | -13.21 | 181.45 | -33.81 | -75.53 | -- |
| Oxford BioMedica plc | 151.21m | -37.07m | 981.32m | 900.00 | -- | 26.33 | -- | 6.49 | -0.3539 | -0.3539 | 1.46 | 0.3084 | 0.6556 | 5.25 | 4.25 | 175,626.00 | -16.95 | -20.23 | -23.87 | -25.48 | 44.12 | 49.36 | -25.85 | -45.03 | 1.67 | -4.81 | 0.7631 | -- | 43.84 | 14.99 | 72.58 | -- | -21.89 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Hargreaves Lansdown Fund Managers Ltd.as of 01 Oct 2025 | 35.35m | 8.10% |
| Conifer Management LLCas of 05 Jun 2025 | 11.66m | 2.67% |
| Lombard Odier Asset Management (Europe) Ltd.as of 05 Jun 2025 | 11.66m | 2.67% |
| IG Markets Ltd.as of 01 Oct 2025 | 11.40m | 2.61% |
| HSBC Global Asset Management (UK) Ltd.as of 01 Oct 2025 | 7.08m | 1.62% |
| Unicorn Asset Management Ltd.as of 01 Oct 2025 | 4.30m | 0.99% |
| AXA Investment Managers UK Ltd.as of 31 Dec 2025 | 3.41m | 0.78% |
| Evelyn Partners Investment Management Services Ltd.as of 01 Oct 2025 | 3.02m | 0.69% |
| HSBC Bank Plc (Market-Maker)as of 01 Oct 2025 | 2.97m | 0.68% |
| Rathbones Investment Management Ltd.as of 01 Oct 2025 | 2.06m | 0.47% |
